Department of Medicine, Division of Infectious Disease, University of Wisconsin School of Medicine & Public Health, 1685 Highland Drive, Centennial Building, 5th Floor, Madison, WI 53705, USA.
Department of Medicine, Division of Infectious Disease, University of Wisconsin School of Medicine & Public Health, 1685 Highland Drive, Centennial Building, 5th Floor, Madison, WI 53705, USA; Department of Medicine, William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA.
Infect Dis Clin North Am. 2019 Jun;33(2):447-466. doi: 10.1016/j.idc.2019.02.010.
Clostridioides difficile infection (CDI) is common in the stem cell transplant (SCT) and hematologic malignancy (HM) population and mostly occurs in the early posttransplant period. Treatment of CDI in SCT/HM is the same as for the general population, with the exception that fecal microbiota transplant (FMT) has not been widely adopted because of safety concerns. Several case reports, small series, and retrospective studies have shown that FMT is effective and safe. A randomized controlled trial of FMT for prophylaxis of CDI in SCT patients is underway. In addition, an abundance of novel therapeutics for CDI is currently in development.
艰难梭菌感染（CDI）在干细胞移植（SCT）和血液恶性肿瘤（HM）患者中很常见，大多发生在移植后早期。SCT/HM 患者中 CDI 的治疗与普通人群相同，只是由于安全性问题，粪便微生物群移植（FMT）尚未广泛采用。一些病例报告、小系列和回顾性研究表明 FMT 是有效且安全的。目前正在进行一项针对 SCT 患者 CDI 预防的 FMT 随机对照试验。此外，目前正在开发大量新型 CDI 治疗药物。
